Serial transplantation unmasks galectin-9 contribution to tumor immune escape in the MB49 murine model.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
04 03 2021
Historique:
received: 24 09 2020
accepted: 15 02 2021
entrez: 5 3 2021
pubmed: 6 3 2021
medline: 18 12 2021
Statut: epublish

Résumé

Mechanisms of tumor immune escape are quite diverse and require specific approaches for their exploration in syngeneic tumor models. In several human malignancies, galectin-9 (gal-9) is suspected to contribute to the immune escape. However, in contrast with what has been done for the infiltrating cells, the contribution of gal-9 produced by malignant cells has never been demonstrated in an animal model. Therefore, we derived isogenic clones-either positive or negative for gal-9-from the MB49 murine bladder carcinoma cell line. A progressive and consistent reduction of tumor growth was observed when gal-9-KO cells were subjected to serial transplantations into syngeneic mice. In contrast, tumor growth was unaffected during parallel serial transplantations into nude mice, thus linking tumor inhibition to the enhancement of the immune response against gal-9-KO tumors. This stronger immune response was at least in part explained by changing patterns of response to interferon-γ. One consistent change was a more abundant production of CXCL10, a major inflammatory factor whose production is often induced by interferon-γ. Overall, these observations demonstrate for the first time that serial transplantation into syngeneic mice can be a valuable experimental approach for the exploration of novel mechanisms of tumor immune escape.

Identifiants

pubmed: 33664349
doi: 10.1038/s41598-021-84270-1
pii: 10.1038/s41598-021-84270-1
pmc: PMC7933353
doi:

Substances chimiques

Chemokine CXCL10 0
Galectins 0
LGALS9 protein, human 0
Interferon-gamma 82115-62-6

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

5227

Références

Bioinformatics. 2012 Aug 15;28(16):2184-5
pubmed: 22743226
Oncogenesis. 2020 Jul 6;9(7):65
pubmed: 32632113
J Pathol. 2018 Aug;245(4):468-477
pubmed: 29732570
Cell. 2016 Sep 8;166(6):1485-1499.e15
pubmed: 27569912
Nat Immunol. 2005 Dec;6(12):1245-52
pubmed: 16286920
PLoS One. 2018 Sep 11;13(9):e0202512
pubmed: 30204750
Cancer Immunol Res. 2016 Dec;4(12):1049-1060
pubmed: 27799141
J Virol. 2013 May;87(9):4835-45
pubmed: 23408620
EMBO Mol Med. 2013 Dec;5(12):1835-51
pubmed: 24142880
J Biosci. 2016 Sep;41(3):507-34
pubmed: 27581941
J Cell Sci. 2018 May 1;131(9):
pubmed: 29717004
Blood. 2019 May 2;133(18):1927-1942
pubmed: 30782612
Blood. 2011 Apr 28;117(17):4501-10
pubmed: 21385853
Genome Biol. 2016 Jul 05;17(1):148
pubmed: 27380939
Immunity. 2014 Aug 21;41(2):270-82
pubmed: 25065622
Clin Cancer Res. 2005 Apr 15;11(8):2962-8
pubmed: 15837748
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Genome Biol. 2014;15(12):550
pubmed: 25516281
Science. 2007 Nov 16;318(5853):1141-3
pubmed: 18006747
J Clin Invest. 2005 May;115(5):1177-87
pubmed: 15841203
J Immunol. 2010 Aug 1;185(3):1383-92
pubmed: 20574007
Blood. 2007 Jun 15;109(12):5346-54
pubmed: 17327412
J Biol Chem. 2015 Jul 3;290(27):16797-811
pubmed: 25947381
Genome Biol. 2010;11(10):R106
pubmed: 20979621
Clin Immunol. 2012 Apr;143(1):51-8
pubmed: 22341088
Tumour Biol. 2015 Aug;36(8):5791-9
pubmed: 25716202
PLoS One. 2012;7(11):e48574
pubmed: 23144904
Cancer Cell. 2019 Jun 10;35(6):885-900.e10
pubmed: 31185212
Nat Med. 2017 May;23(5):556-567
pubmed: 28394331
Nat Biotechnol. 2014 Sep;32(9):896-902
pubmed: 25150836
Melanoma Res. 2016 Oct;26(5):429-41
pubmed: 27455380
Pancreas. 2018 Oct;47(9):e59-e60
pubmed: 30199489
EBioMedicine. 2017 Aug;22:44-57
pubmed: 28750861
Oncotarget. 2018 Apr 20;9(30):21036-21051
pubmed: 29765518
Blood. 2009 Feb 26;113(9):1957-66
pubmed: 19005181

Auteurs

Valentin Baloche (V)

CNRS, UMR 9018, Gustave Roussy and Université Paris-Saclay, 39 Rue Camille Desmoulins, F-94805, Villejuif, France.

Julie Rivière (J)

Inserm, U1170, Gustave Roussy, 39 Rue Camille Desmoulins, F-94805, Villejuif, France.

Thi Bao Tram Tran (TBT)

CNRS, UMR 9018, Gustave Roussy and Université Paris-Saclay, 39 Rue Camille Desmoulins, F-94805, Villejuif, France.

Aurore Gelin (A)

CNRS, UMR 9018, Gustave Roussy and Université Paris-Saclay, 39 Rue Camille Desmoulins, F-94805, Villejuif, France.

Olivia Bawa (O)

Plateforme de pathologie expérimentale et translationnelle, UMS AMMICA, Gustave Roussy, 39 Rue Camille Desmoulins, F-94805, Villejuif, France.

Nicolas Signolle (N)

Plateforme de pathologie expérimentale et translationnelle, UMS AMMICA, Gustave Roussy, 39 Rue Camille Desmoulins, F-94805, Villejuif, France.

M Boyba Khadija Diop (MBK)

Plateforme de Bioinformatique, UMS AMMICA, Gustave Roussy, 39 Rue Camille Desmoulins, F-94805, Villejuif, France.

Philippe Dessen (P)

Plateforme de Bioinformatique, UMS AMMICA, Gustave Roussy, 39 Rue Camille Desmoulins, F-94805, Villejuif, France.

Stéphanie Beq (S)

HiFiBiO Therapeutics, Pépinière Paris Santé Cochin, 29 Rue du Faubourg Saint-Jacques, F-75014, Paris, France.

Muriel David (M)

HiFiBiO Therapeutics, Pépinière Paris Santé Cochin, 29 Rue du Faubourg Saint-Jacques, F-75014, Paris, France.

Pierre Busson (P)

CNRS, UMR 9018, Gustave Roussy and Université Paris-Saclay, 39 Rue Camille Desmoulins, F-94805, Villejuif, France. Pierre.Busson@gustaveroussy.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH